The global immunodiagnostics market is projected to reach a valuation of US$ 23.4 Bn in 2025 and expand to US$ 38.1 Bn by 2032, registering a CAGR of 7.2% during the forecast period. According to Persistence Market Research, immunodiagnostics has become a cornerstone of modern clinical diagnostics, providing highly sensitive and rapid detection of disease-specific biomarkers. It is increasingly used in disease prevention strategies, patient monitoring, and personalized healthcare delivery.
Key market growth drivers include rising global disease burden, growing adoption of precision medicine, and a shift toward decentralized testing. Among all applications, oncology and endocrinology is expected to remain the leading segment in 2025, holding approximately 29.5% share, driven by increasing cancer incidence and regulatory approvals for oncology-focused assays. North America will lead geographically, supported by strong R&D investments, advanced diagnostic infrastructure, and post-COVID acceleration of home-based and point-of-care testing adoption.
Key Highlights from the Report
➤ Immunodiagnostics market size projected at US$ 38.1 Bn by 2032, growing at 7.2% CAGR from 2025.
➤ Oncology and endocrinology to hold ~29.5% share in 2025 due to high cancer and endocrine disorder prevalence.
➤ North America to dominate with 38.3% share, driven by automation, precision diagnostics, and home testing.
➤ Reagents and consumables to account for 54.2% of market share in 2025 owing to recurring usage.
➤ AlphaLISA technology creating high-sensitivity, low-volume testing opportunities.
➤ IVDR compliance in Europe driving innovation and new assay launches.
✅𝐆𝐞𝐭 𝐚 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲 𝐨𝐟 𝐑𝐞𝐬𝐞𝐚𝐫𝐜𝐡 𝐑𝐞𝐩𝐨𝐫𝐭
Market Segmentation by Product Type
In terms of product type, the immunodiagnostics market is segmented into instruments and reagents & consumables. Reagents and consumables are expected to hold a commanding 54.2% share in 2025. Their recurring use in various tests—ranging from infectious diseases to oncology—ensures stable revenue streams for diagnostic companies. Proprietary formulations of reagents also foster brand loyalty and long-term customer retention.
Instruments, while representing a smaller share, are critical enablers of automation, high-throughput testing, and integration with Laboratory Information Systems (LIS). The demand for multi-disease platforms and advanced chemiluminescence analyzers is steadily increasing, particularly in hospital laboratories and large reference labs that require precision, scalability, and rapid turnaround times.
Market Segmentation by Application
The application segment covers infectious diseases, oncology and endocrinology, bone and mineral diseases, autoimmunity disorders, cardiac biomarkers, drug monitoring, and others. Among these, oncology and endocrinology will continue to dominate the market due to the clinical emphasis on early detection and monitoring of cancer and hormonal disorders. Immunoassays enable precise measurement of tumor-associated antigens and hormone levels at extremely low concentrations.
Infectious diseases remain another high-growth area, fueled by emerging pathogen mutations, antimicrobial resistance, and global health initiatives. Post-pandemic investment in diagnostic infrastructure, especially for tuberculosis, HIV, hepatitis, and respiratory viruses, has positioned immunodiagnostics as a core component of public health response strategies.
Regional Insights
North America – The region will command around 38.3% market share in 2025, driven by rapid adoption of high-throughput platforms and growing preference for home and point-of-care testing. The U.S. leads in regulatory approvals, infrastructure, and reimbursement support for immunodiagnostic assays.
Europe – Growth is supported by population screening programs, value-based healthcare models, and the implementation of In Vitro Diagnostic Regulation (IVDR). Countries like Germany, France, and the U.K. are investing heavily in early detection for cancer and cardiovascular conditions, spurring demand for advanced assays.
Asia Pacific – Markets in China and India are expanding quickly, aided by government health programs like Ayushman Bharat and manufacturing incentives under the PLI Scheme. Local production and public-private partnerships are fostering accessibility and affordability of immunodiagnostics.
Market Drivers
Growing incidence of chronic and infectious diseases such as HIV, hepatitis, and cancer is the most prominent growth driver. These conditions require early, precise detection, and immunoassays offer the necessary sensitivity to detect biomarkers at trace levels. Post-COVID, there has been a notable push toward preventive healthcare, which further accelerates immunodiagnostics adoption.
Another factor is the rising demand for personalized medicine, where targeted diagnostics guide patient-specific treatment decisions. Government-funded screening initiatives in emerging markets also significantly expand testing coverage and market penetration.
Market Restraints
The major challenge facing the industry is false-positive results caused by antigen cross-reactivity. In areas where multiple pathogens coexist—such as tropical regions with dengue, Zika, and chikungunya—antibody-based assays can produce misleading results. This can delay treatment or necessitate costly confirmatory testing.
Additionally, regulatory compliance costs—especially under frameworks like IVDR—are pushing smaller players out of the market. For some regions, lack of skilled laboratory personnel and high equipment costs remain significant hurdles.
Market Opportunities
Technological advancements like AlphaLISA are unlocking new opportunities in low-volume, high-sensitivity testing. Its capability to detect biomarkers at femtogram levels without interference offers huge potential for applications in autoimmune and infectious diseases.
There is also a growing opportunity in multiplex testing, enabling simultaneous detection of multiple disease markers from a single sample. Coupled with AI-assisted interpretation, this can revolutionize rapid diagnostics in both centralized and decentralized healthcare settings.
Reasons to Buy the Report
✔ Comprehensive market size and forecast data for 2025–2032.
✔ In-depth segmentation by product type, application, and region.
✔ Analysis of key technological innovations like AlphaLISA.
✔ Detailed competitive landscape with company profiles.
✔ Insights into regulatory trends and their market implications.
Company Insights
✦ Abbott
✦ Roche Diagnostics
✦ DiaSorin
✦ Danaher Corporation
✦ QIAGEN
✦ bioMérieux
✦ Thermo Fisher Scientific
✦ Quest Diagnostics
✦ Siemens Healthineers AG
✦ Bio-Rad Laboratories, Inc.
✦ Sysmex Corporation
✦ PerkinElmer, Inc.
✦ Agilent Technologies, Inc.
✦ Mindray Medical International Limited
✦ Grifols, S.A.
✦ Becton, Dickinson and Company (BD)
✦ Abcam plc
✦ Merck KGaA
✦ Enzo Biochem, Inc.
✦ Bio-Techne Corporation
✦ Meso Scale Diagnostics, LLC.
✦ GenScript Biotech Corporation
✦ Myriad Genetics, Inc.
✦ Others
Recent Developments
September 2024: DiaSorin launched the LIAISON S. pneumoniae Antigen Immunodiagnostic Assay, aiding in pneumococcal pneumonia diagnosis.
January 2024: Fujirebio Holdings and Agappe Diagnostics entered a CDMO collaboration to produce cartridge-based CLIA reagents for Mispa i60 and Mispa i121 systems.
Conclusion
The immunodiagnostics market is on a solid growth trajectory, driven by rising disease prevalence, the global shift toward preventive care, and rapid technological innovation. With revenues expected to climb from US$ 23.4 Bn in 2025 to US$ 38.1 Bn by 2032, the sector will continue to benefit from advancements in high-sensitivity assay technologies, automation, and decentralized testing models.
While challenges such as false positives and regulatory compliance persist, ongoing R&D and next-generation solutions like AlphaLISA are set to address these hurdles, improving both accuracy and efficiency. Regional leaders like North America and fast-growing markets in Asia Pacific will shape competitive strategies, while segments like oncology and endocrinology will remain key revenue drivers.
Read Related Reports:
Biomarker Discovery Outsourcing Services Market
Biopsy Devices Market
